OCS OCULIS HOLDING AG

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

ZUG, Switzerland, March 14, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to annual equity incentive awards granted to members of the executive committee of the Company, as well as purchase of ordinary shares by a member of the Company´s Board of Direcors.

Attachments



EN
14/03/2025

Underlying

OCSOCULIS HOLDING AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OCULIS HOLDING AG

 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Publishes Notifications of Transactions by Persons Discharging ...

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities ZUG, Switzerland, Oct. 08, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company. Attachment

23h / 51m 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Accelerates Privosegtor into Registrational Trials in Acute Opt...

Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch the PIONEER Program, which includes multiple global trials intended to support registrations in AON and NAION Company to host conference call and webcast at 8:30 AM ET today Oculis H...

October 6, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis hrindir af stað skráningarrannsóknum á Privosegtor við bráðri s...

Oculis hrindir af stað skráningarrannsóknum á Privosegtor við bráðri sjóntaugabólgu, sem gæti orðið fyrsta taugaverndandi meðferð sinnar tegundar ZUG, Sviss, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Árangursríkur fundur með Matvæla- og lyfjastofnun Bandaríkjanna (FDA) skapar möguleika á að hefja skráningarrannsóknir á Privosegtor sem meðferð við bráðri sjóntaugabólgu (e. Acute Optic Neuritis, AON) og blóðþurrð í sjóntaug án slagæðabólgu (e. Non-arteritic Anterior Ischaemic Optic Neuropathy, NAION) Oculis er að hleypa af stokkunum PIONEER-áætluninni, sem felur í sér alþjóðlegar skráningarrannsók...

October 6, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Accelerates Privosegtor into Registrational Trials in Acute Opt...

Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch the PIONEER Program, which includes multiple global trials intended to support registrations in AON and NAION Company to host conference call and webcast at 8:30 AM ET today ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Oculis H...

October 6, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Publishes Notification of Transactions by Person Discharging Ma...

Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities ZUG, Switzerland, Sept. 26, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to trades entered into by a PDMR of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934, as amended. Attachment

September 26, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch